In this case, targeting the upstream cytokines, such as IL-12 and IL-23 simultaneously or IL-23 alone, that stimulate the ILCs to produce IL-17 and IFN-γ may serve as a more effective strategy in treating patients with Crohn’s disease (Sands et al., 2017; Rutgeerts et al., 2018). Here, IL17A is linked to Crohn disease.